X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Twist Biopharma, will leverage its Library of Libraries to conduct antibody discovery campaigns against targets to be determined by Bayer. Bayer will have the option to license antibodies discovered under the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $188.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2023
Details:
Under the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against targets identified by Ono for the treatment of autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 31, 2023
Details:
Under the terms of the collaboration, Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.
Lead Product(s): Antibody
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 20, 2023
Details:
Alpaca-derived VHH antibody is a heavy chain antibody fragment (VHH), anti-SARS-CoV-2 nanobody (saRBD-1), that disrupts spike glycoprotein of SARS-CoV-2 interaction with human ACE 2 by competitively binding to the spike protein receptor-binding domain.
Lead Product(s): Alpaca-derived VHH Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options, identified by Astellas.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023
Details:
Under the terms of the agreement, Ildong will license a suite of Twist’s VHH antibody libraries for a period of three years and will use the libraries to conduct research and development activities.
Lead Product(s): VHH Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ildong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2022
Details:
Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary Twist antagonist antibodies, targeting an undisclosed checkpoint inhibitor pathway in the tumor microenvironment, as potential therapeutic candidates.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 09, 2022
Details:
Under the collaboration, Twist will leverage its proprietary Library of Libraries to discover 5 novel antibodies. MediSix will use its platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any CAR T-cell fractricide.
Lead Product(s): T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MediSix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 07, 2022
Details:
Twist Biopharma, expects to leverage its antibody discovery and optimization platform to discover novel antibodies against specific targets of interest that will be engineered into Kriya’s proprietary gene therapy technology platform for durable and targeted delivery.
Lead Product(s): Antibody,AAV-based Gene Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Kriya Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2022
Details:
Twist intends to use the net proceeds of the offering, along with its existing cash, cash equivalents and short-term investments to scale its investment in its research and development organization, which includes investing in pharmaceutical biologics drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
